Skip to main content
Clinical Trials/NCT00644852
NCT00644852
Completed
Not Applicable

Medical Chart Review of Patients on Long-term Treatment With Long-acting Injectable Risperidone

Johnson & Johnson Taiwan Ltd0 sites342 target enrollmentJanuary 2007

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Schizophrenia
Sponsor
Johnson & Johnson Taiwan Ltd
Enrollment
342
Primary Endpoint
Compare the number of days hospitalized for reasons relating to psychosis before and after treatment with risperidone long-acting injectable.
Status
Completed
Last Updated
11 years ago

Overview

Brief Summary

The purpose of the study is to evaluate the characteristics, clinical responses, and safety issues of patients receiving long-term treatment of Risperidone long-acting injectable. The goal is to evaluate patient outcomes based on pre-existing risk or disease factors and past medication use.

Detailed Description

This is an Observational, retrospective study on the use of Risperidone long-acting injectable. The purpose of the study is to evaluate the characteristics, clinical responses, and safety issues of patients receiving long-term treatment of Risperidone. Patient outcomes will be evaluated based on pre-existing risk or disease factors and past medication use. Data will be collected from medical charts and other available medical records from one year prior to risperidone treatment until discontinuation of risperidone long acting injectable. The study will compare the number of days hospitalized for reasons relating to psychosis before and after treatment with risperidone long-acting injectable. Information about past use of anti-psychotic medications will be collected. The occurrence and frequency of adverse events \[Extra-Pyramidal Symptoms (EPS) - the abnormal body movements sometimes associated with antipsychotic medications, body weight changes, drowsiness, sexual problems\] and the dose or change in dose of Risperidone long-acting injectable will also be collected. The study will also investigate the relapse rate and the hospitalization rate before and after treatment. It is a chart review type of study. No study drug has been used in the study.

Registry
clinicaltrials.gov
Start Date
January 2007
End Date
September 2007
Last Updated
11 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • Diagnosis of Schizophrenia or Schizoaffective disorder by DSM-IV-TR criteria
  • Patients who used to be treated with Risperidone long-acting injectable regularly for at least 3 months
  • Patients whose medical charts or other medical records are available

Exclusion Criteria

  • Not provided

Outcomes

Primary Outcomes

Compare the number of days hospitalized for reasons relating to psychosis before and after treatment with risperidone long-acting injectable.

Time Frame: From one year prior to risperidone treatment until discontinuation of risperidone long acting injectable.

Secondary Outcomes

  • Compare the Relapse Rate and the Hospitalization Rate before patients were treated with risperidone long-acting injectable(1 year)

Similar Trials